SCHEMBL17818392

SCHEMBL17818392

C#Cc1cccc(NC(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
NPC1 O15118 4/20 0.69
RAB9A P51151 4/20 0.69
TDP1 Q9NUW8 2/20 0.69
P2RX1 P51575 2/20 0.67
KCNK3 O14649 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.54
HDAC3 O15379 1/20 0.54
EGFR P00533 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16236279 0.87 NPC1 (0.67) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL5612900 0.86 KCNK3 (0.69) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL22627078 0.86 MEN1 (0.61) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL15907203 0.85 MEN1 (0.54) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL13692718 0.85 KCNK9 (0.55) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL17818378 0.85 NPC1 (0.56) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL17818385 0.85 MEN1 (0.71) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL3838614 0.84 HDAC1 (0.66) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL24628772 0.83 DEGS1 (0.56) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL17818365 0.83 MAPT (0.66) MEN1KMT2ANPC1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997030-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-08-09 EP disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 US disclosed
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS RET, DCK, PRKD2 MEN1 3235/4885KMT2A 1498/4885NPC1 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.